← Patent-cliff monitor small molecule ALECENSA ALECTINIB HYDROCHLORIDE
Loss of exclusivity April 2035 latest FDA-listed patent expiry
Company HOFFMANN-LA ROCHE INC
Drug detail Brand name ALECENSA Active ingredient ALECTINIB HYDROCHLORIDE Strength EQ 150MG BASE Dosage form CAPSULE Route ORAL Modality Small molecule FDA approval December 2015 Marketing status RX
Listed patents Patent Expires Type 10350214 April 2035 product 11433076 April 2035 product 9365514 March 2032 product 9126931 May 2031 substance 9440922 June 2030 product
Regulatory exclusivity Code Expires ODE-477 April 2031 I-947 April 2027
Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.